Skip to content
DataLookout
Menu

AURORANCT06602479

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

StatusActive, Not Recruiting
PhasePhase 2
SponsorAbbVie
Primary completion (estimated)

At risk: Primary completion moved at least 45 days later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 8 more changesShow less
    • Eligibility criteria expanded, about 29 words
    • Enrollment closed, study ongoing
    • Primary completion pushed from Dec 18, 2026 to Feb 2027
    • Trial sites expanded: 54 → 71 locations
    • Final enrollment: 309 participants (planned 488)
    • Study completion moved earlier from May 7, 2027 to Feb 2027
    • Secondary endpoints: details revised at 6 of 6 entries
    • Study description expanded, about 5 words
  2. Minor Site details revised at 20 of 54 sitesv12
  3. Notable Eligibility criteria expanded, about 63 wordsv11 Show 5 more changesShow less
    • Enrollment target: 408 to 488
    • Study sites: 60 to 54
    • Secondary endpoints: 3 to 6
    • Study description expanded, about 7 words
    • Collaborators shortened, about 1 word
  4. Notable Trial status: Active, Not Recruiting to Recruitingv10 Show 4 more changesShow less
    • Enrollment target: 12 to 408
    • Primary completion date: Sep 15, 2025 to Dec 18, 2026
    • Study sites: 54 to 60
    • Study completion date: Sep 15, 2025 to May 7, 2027
  5. Notable Lead sponsor: AstraZeneca to AbbVie
    • Collaborators expanded, about 1 word
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Minor Study sites: 55 to 54v8
  2. Notable Enrollment target: estimated 408 to confirmed 12
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 61 to 55
    • Primary and study completion dates: Sep 7, 2026 to Sep 15, 2025
    v7
  3. Minor Study sites: 60 to 61v6
  4. Minor Site details revised at 13 of 60 sitesv5
  5. Minor Study sites: 59 to 60v4
  6. Minor Site details revised at 8 of 59 sitesv3
  7. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Sep 2, 2026 to Sep 7, 2026
    • Start date changed from estimate of Oct 2, 2024 to Oct 7, 2024
    • Site details revised at 59 of 59 sites
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Efficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine
Timeframe: Up to approximately Week 12
Number of Participants with Adverse Events (AEs)
Timeframe: Up to approximately Day 141

Secondary (3)

Efficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine as proportion of patients
Effect of repeat doses of MEDI0618 on disability caused by migraine headaches
Effect of repeat doses of MEDI0618 on the severity of migraine headaches

Arms and interventions

aCGRP-N_MEDI0618 (Dose A)Experimental

In the aCGRP-N cohort, 128 participants will be randomised on a 1:1 basis to receive MEDI0618 Dose A or placebo. After 104 participants total have been randomised, 3 other dose arms with MEDI0618 will be initiated and include 24 participants each.

aCGRP-N_PlaceboPlacebo comparator

In the aCGRP-N cohort, 128 participants will be randomised on a 1:1 basis to receive MEDI0618 Dose A or placebo. After 104 participants total have been randomised, 3 other dose arms with MEDI0618 will be initiated and include 24 participants each.

aCGRP-N_MEDI0618 (Dose B)Experimental

After 104 participants total have been randomised on Dose A and placebo arms, MEDI0618 will be initiated and include 24 participants each on active dose arm.

aCGRP-N_MEDI0618 (Dose C)Experimental

After 104 participants total have been randomised on Dose A and placebo arms, MEDI0618 will be initiated and include 24 participants each on active dose arm.

aCGRP-N_MEDI0618 (Dose D)Experimental

After 104 participants total have been randomised on Dose A and placebo arms, MEDI0618 will be initiated and include 24 participants each on active dose arm.

aCGRP-IR_MEDI0618 (Dose A)Experimental

In the aCGRP-IR cohort there will be 1:1 randomisation of participants (50 to MEDI0618 and 50 to placebo).

aCGRP-IR_PlaceboPlacebo comparator

In the aCGRP-IR cohort there will be 1:1 randomisation of participants (50 to MEDI0618 and 50 to placebo).

Drugs: MEDI0618, Placebo

Sites

71 sites in 8 countries

United States 34, Poland 10, Czechia 8, Spain 6, Germany 5, Italy 4, Hungary 3, Denmark 1